Micronutrients & recovery
Current anti-obesity medication (AOM) studies frequently misrepresent skeletal muscle mass (SMM) loss by using DXA or BIA to estimate fat-free mass (FFM) or lean mass, which includes bone and non-skeletal tissues, thereby confounding the assessment of clinically significant muscle loss.
When reading studies on weight loss drugs (like GLP-1 agonists) that report 'muscle loss' based on DXA or bioimpedance scales, recognize that these numbers likely overestimate true skeletal muscle loss because they include bone and water. True muscle loss is likely lower than reported in these specific studies. Look for studies using MRI or CT for accurate skeletal muscle quantification.
Most randomized, placebo- controlled studies addressing this question report on fat- free or lean mass estimated from dual- energy x- ray absorptiometry or bioelectrical impedance without defining the composition of these components. Fat- free, lean, and skeletal muscle mass are not synonymous terms, and studies frequently fail to define lean mass, which may or may not include bone.
Why this rating
Based on a comprehensive narrative review of multiple RCTs and established biophysical principles of body composition.
Source
Understanding Impact of Anti‐Obesity Medications on Skeletal Muscle Mass Change Is Confounded by Measurement Methods
Arden McMath et al. · Obesity Reviews · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →